Edgar Filing: BIOGEN IDEC INC. - Form 8-K

BIOGEN IDEC INC. Form 8-K February 11, 2011

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2011 Biogen Idec Inc.

(Exact name of registrant as specified in its charter)

Delaware0-1931133-0112644(State or other jurisdiction
of incorporation)(Commission
file number)(IRS Employer
Identification No.)

133 Boston Post Road, Weston, Massachusetts

02493

(Address of principal executive offices)

(Zip Code)

Registrant s telephone number, including area code: (781) 464-2000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

<u>Item 8.01 Other Events</u> <u>SIGNATURES</u>

Edgar Filing: BIOGEN IDEC INC. - Form 8-K

Table of Contents

Item 8.01 Other Events

On February 11, 2011, Biogen Idec Inc. announced that its Board of Directors has authorized the repurchase of up to 20 million shares of its common stock. The company expects to use this repurchase program principally to offset common stock issuances under its share-based compensation plans. This repurchase program does not have an expiration date.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biogen Idec Inc.

By: /s/ Robert A. Licht Robert A. Licht Senior Vice President

Date: February 11, 2011